SORIN COMPLETES ENROLLMENT OF JUPITER II TRIAL ON JANUS CARBOSTENT

Sorin, a European medical technology company specializing in the treatment of cardiovascular diseases, has completed enrollment of its JUPITER II clinical trial.

JUPITER II is an international, multicenter, double-blind, randomized clinical trial investigation for the treatment of stenosis of coronary lesions with Janus Carbostent. The trial involves 331 patients in 16 European centers. The goal of the study is to further strengthen clinical data about the safety and effectiveness of Janus in the treatment of atherosclerotic lesions, in native coronary arteries of patients with ischemic cardiovascular disease, using state of the art implantation techniques (direct stenting).

Janus is the only drug-eluting stent on the market that combines the benefits of Carbofilm, Sorin's turbostatic carbon-based highly biocompatible coating, with a proprietary, nonpolymer drug release mechanism.